| Literature DB >> 34088878 |
Bruce Anthony Campbell Cree1, Douglas L Arnold2, Jeremy Chataway3,4, Tanuja Chitnis5, Robert J Fox6, Angela Pozo Ramajo7, Niamh Murphy8, Hans Lassmann9.
Abstract
In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive multiple sclerosis (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunological, or pathological criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools which, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS.Entities:
Year: 2021 PMID: 34088878 DOI: 10.1212/WNL.0000000000012323
Source DB: PubMed Journal: Neurology ISSN: 0028-3878 Impact factor: 9.910